南方科技大学知识苑(SUSTech KC): Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World

题名	Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World
作者	Zhao, Fang; Rao, Man; Chen, Weimei; Cai, Kanru; Zhang, Lukun; Xu, Liumei; Sun, Liqing; Liu, Xiaoning; He, Yun; Wang, Hui
通讯作者	Wang, Hui
发表日期	2022-10-01
DOI	10.1097/QAI.0000000000003053
发表期刊	JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 影响因子和分区
ISSN	1525-4135
EISSN	1077-9450
卷号	91
摘要	Background: Some inpatients with HIV-RNA >= 500,000 copies/mL in China need to use 2-drug regimen for some reasons, although limited data are available for dolutegravir plus lamivudine (3TC) in those patients with ultra-high viral loads. Methods: We conducted a single-center retrospective-prospective study in China and enrolled 42 ART-naive HIV-infected inpatients who use a once-daily 2-drug regimen because of various reasons (drug interaction, renal impairment, age, and other related comorbidities).They were divided into 2 groups, low viral load group (baseline viral load <500,000 copies/mL, n = 20) and high viral load group (baseline viral load >= 500,000 copies/mL, n = 22). All patients were followed up for 48 weeks. Results: The median of baseline viral load was 5.74 log(10) copies/mL and CD4(+) T-cell count was 59 cells/mu L. At week 48, there was no significant difference (P = 0.598) in proportions of participants with HIV-1 RNA <50 copies/mL [90%, 95% confidence interval (CI) (75.6% to 104.4%) in low viral load groups vs 95.5%, 95% CI (86.0% to 104.9%) in high viral load groups]. No differences were found in mean increase of CD4(+) T-cell count from baseline between 2 groups (218 +/- 122 vs 265 +/- 127 cells/mu L, P = 0.245). There is no grade 3 or higher treatment-related adverse events and none discontinued treatment because of adverse events. Conclusions: The results of our study in real world support dolutegravir + 3TC dual regimen as a promising therapy option for treatment-naive HIV-infected patient with baseline viral load >= 500,000 copies/mL.
关键词	HIV-1 AIDS dolutegravir plus lamivudine dual drug regimen high viral load
相关链接	[来源记录]
收录类别	SCI
语种	英语
学校署名	第一 ; 通讯
资助项目	Sanming Project of Medicine in Shenzhen[SZSM201512029] ; Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialities[SZGSP011]
WOS研究方向	Immunology ; Infectious Diseases
WOS类目	Immunology ; Infectious Diseases
WOS记录号	WOS:000852773800003
出版者	LIPPINCOTT WILLIAMS & WILKINS
ESI学科分类	IMMUNOLOGY
来源库	Web of Science
引用统计	被引频次[WOS]：4
成果类型	期刊论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/401495
专题	南方科技大学第二附属医院南方科技大学第一附属医院
作者单位	Southern Univ Sci & Technol, Natl Clin Res Ctr Infect Dis, State Key Discipline Infect Dis, Dept Infect Dis,Shenzhen Peoples Hosp 3,Hosp 2, Shenzhen, Guangdong, Peoples R China
第一作者单位	南方科技大学第二附属医院; 南方科技大学第一附属医院
通讯作者单位	南方科技大学第二附属医院; 南方科技大学第一附属医院
第一作者的第一单位	南方科技大学第二附属医院; 南方科技大学第一附属医院
推荐引用方式 GB/T 7714	Zhao, Fang,Rao, Man,Chen, Weimei,et al. Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES,2022,91.
APA	Zhao, Fang.,Rao, Man.,Chen, Weimei.,Cai, Kanru.,Zhang, Lukun.,...&Wang, Hui.(2022).Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World.JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES,91.
MLA	Zhao, Fang,et al."Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World".JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES 91(2022).